Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Return on Equity (2023 - 2025)

Compass Therapeutics' Return on Equity history spans 3 years, with the latest figure at 0.35% for Q4 2025.

  • For Q4 2025, Return on Equity rose 5.0% year-over-year to 0.35%; the TTM value through Dec 2025 reached 0.35%, up 5.0%, while the annual FY2025 figure was 0.45%, 4.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.35% at Compass Therapeutics, up from 0.46% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.28% in Q4 2023 and bottomed at 0.65% in Q2 2025.
  • The 3-year median for Return on Equity is 0.35% (2025), against an average of 0.4%.
  • The largest YoY upside for Return on Equity was 5bps in 2025 against a maximum downside of -34bps in 2025.
  • A 3-year view of Return on Equity shows it stood at 0.28% in 2023, then plummeted by -45bps to 0.4% in 2024, then grew by 12bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Return on Equity are 0.35% (Q4 2025), 0.46% (Q3 2025), and 0.65% (Q2 2025).